Efficacy and safety of retreatment with Elbasvir/Grazoprevir associated to Sofosbuvir plus /- Ribavirin in HCV infected patients with a previous failure to therapy with direct-acting antiviral drugs

被引：0
|
作者：
Alric, Laurent [1 ]
Leroy, Vincent [2 ]
Cotte, Laurent [3 ]
Anne, Minello [4 ]
Remy, Andre Jean [5 ]
Rouanet, Isabelle [6 ]
Godart, Marion [1 ]
Hezode, Christophe [7 ]
Abravanel, Florence [8 ]
Ollivier-Hourmand, Isabelle [9 ]
机构：
[1] CHU Purpan, Internal Med Digest Dept, Toulouse, France
[2] CHU, Digest Dept, Grenoble, France
[3] Hop Lyon, Digest Dept, Lyon, France
[4] CHU, Digest Dept, Dijon, France
[5] Hop Perpignan, Digest Dept, Perpignan, France
[6] CHU, Digest Dept, Nimes, France
[7] CHU Henri Mondor, Digest Dept, Creteil, France
[8] CHU Purpan, Virol, Toulouse, France
[9] CHU, Digest Dept, Caen, France
来源：
HEPATOLOGY | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1544
引用
收藏
页码：824A / 825A
页数：2
相关论文
共 50 条
  • [21] Retreatment with sofosbuvir plus grazoprevir plus elbasvir plus ribavirin of patients with Hepatitis C virus Genotype 1 or 4 with RASs at failure of a sofosbuvir plus ledipasvir or plus daclatasvir or plus simeprevir regimen (ANRS HC34 REVENGE study)
    Laforest, C.
    Fougerou-Leurent, C.
    Pawlotsky, J. M.
    Hezode, C.
    Pol, S.
    Renault, A.
    Alric, L.
    Larrey, D.
    Metivier, S.
    Tran, A.
    Jezequel, C.
    Samuel, D.
    Zoulim, F.
    Pailhe, A.
    Gibowski, S.
    Bourliere, M.
    Bellissant, E.
    De Ledinghen, V.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2017, 31 : 36 - 36
  • [22] Safety and Efficacy of Direct-Acting Antiviral Drugs in Patients with Haemoglobinophaties and Chronic Hepatitis C Infection
    Piga, Antonio
    Rigano, Paolo
    Origa, Raffaella
    Cappellini, M. Domenica
    Pinto, Valeria
    Tartaglione, Immacolata
    Filosa, Aldo
    D'Ascola, Domenico
    Di Marco, Vito
    Forni, Gian Luca
    BLOOD, 2016, 128 (22)
  • [23] SUCCESSFUL RETREATMENT WITH SOFOSBUVIR-CONTAINING REGIMENS FOR HCV GENOTYPE 2 OR 3 INFECTED PATIENTS WHO FAILED PRIOR SOFOSBUVIR PLUS RIBAVIRIN THERAPY
    Esteban, R.
    Nyberg, L.
    Lalezari, J.
    Ni, L.
    Doehle, B.
    Kanwar, B.
    Brainard, D.
    Subramanian, M.
    Symonds, W. T.
    McHutchison, G.
    Rodriquez-Torres, M.
    Zeuzem, S.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S4 - S5
  • [24] Retreatment with sofosbuvir plus grazoprevir plus elbasvir plus ribavirin of patients with Hepatitis C virus Genotype 1 or 4 with RASs at failure of a sofosbuvir plus ledipasvir or plus daclatasvir or plus simeprevir regimen (ANRS HC34 REVENGE study)
    de Ledinghen, Victor
    Laforest, Claire
    Hezode, Christophe
    Pol, Stanislas
    Renault, Alain
    Alric, Laurent
    Larrey, Dominique G.
    Metivier, Sophie
    Tran, Albert
    Jezequel, Caroline
    Samuel, Didier
    Zoulim, Fabien
    Pailhe, Aurelie
    Gibowski, Severine
    Bourliere, Marc
    Bellissant, Eric
    Pawlotsky, Jean-Michel
    HEPATOLOGY, 2016, 64 (06) : 1130A - 1130A
  • [25] Efficacy of 12 or 18weeks of elbasvir plus grazoprevir with ribavirin in treatment-naive, noncirrhotic HCV genotype 3-infected patients
    Gane, E.
    Nahass, R.
    Luketic, V.
    Asante-Appiah, E.
    Hwang, P.
    Robertson, M.
    Wahl, J.
    Barr, E.
    Haber, B.
    JOURNAL OF VIRAL HEPATITIS, 2017, 24 (10) : 895 - 899
  • [26] Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens
    Wilson, Eleanor M.
    Kattakuzhy, Sarah
    Sidharthan, Sreetha
    Sims, Zayani
    Tang, Lydia
    McLaughlin, Mary
    Price, Angie
    Nelson, Amy
    Silk, Rachel
    Gross, Chloe
    Akoth, Elizabeth
    Mo, Hongmei
    Subramanian, G. Mani
    Pang, Phillip S.
    McHutchison, John G.
    Osinusi, Anu
    Masur, Henry
    Kohli, Anita
    Kottilil, Shyam
    CLINICAL INFECTIOUS DISEASES, 2016, 62 (03) : 280 - 288
  • [27] C-SCAPE: EFFICACY AND SAFETY OF 12 WEEKS OF GRAZOPREVIR plus /- ELBASVIR plus /- RIBAVIRIN IN PATIENTS WITH HCV GT2, 4, 5 OR 6 INFECTION
    Brown, A.
    Hezode, C.
    Zuckerman, E.
    Foster, G.
    Zekry, A.
    Roberts, S.
    Howe, A.
    Durkan, C.
    Badshah, C.
    Zhang, B.
    Robertson, M.
    Wahl, J.
    Barr, E.
    Haber, B.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S619 - S619
  • [28] Patients with HCV genotype-1 who have failed a direct-acting antiviral regimen: virological characteristics and efficacy of retreatment
    Pisaturo, Mariantonietta
    Starace, Mario
    Minichini, Carmine
    De Pascalis, Stefania
    Macera, Margherita
    Occhiello, Laura
    Messina, Vincenzo
    Sangiovanni, Vincenzo
    Claar, Ernesto
    Precone, Davide
    Stornaiuolo, Gianfranca
    Stanzione, Maria
    Gentile, Ivan
    Brancaccio, Giuseppina
    Martini, Salvatore
    Masiello, Addolorata
    Megna, Angelo Salomone
    Coppola, Carmine
    Federico, Alessandro
    Sagnelli, Evangelista
    Persico, Marcello
    Lanza, Alfonso Galeota
    Marrone, Aldo
    Gaeta, Giovanni Battista
    Coppola, Nicola
    ANTIVIRAL THERAPY, 2019, 24 (07) : 485 - 493
  • [29] Microbial translocation and T cell activation are modified by direct-acting antiviral therapy in HCV-infected patients
    Lattanzi, Barbara
    Baroncelli, Silvia
    De Santis, Adriano
    Galluzzo, Clementina Maria
    Mennini, Gianluca
    Michelini, Zuleika
    Lupo, Marinella
    Corradini, Stefano Ginanni
    Rossi, Massimo
    Palmisano, Lucia
    Merli, Manuela
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 48 (10) : 1146 - 1155
  • [30] Immunological Dynamics Associated with Direct-Acting Antiviral Therapies in Naive and Experimented HCV Chronic-Infected Patients
    Pereira, Grenda Leite
    Tarrago, Andrea Monteiro
    Lima Neves, Walter Luiz
    da Silva Neto, Pedro Vieira
    de Souza, Priscila Sarmento
    Affonso, Juliana dos Santos
    de Sousa, Keyla Santos
    da Silva, Jessica Albuquerque
    Costa, Allyson Guimaraes
    Victoria, Flamir da Silva
    Victoria, Marilu Barbieri
    Malheiro, Adriana
    MEDIATORS OF INFLAMMATION, 2019, 2019
12345